2型糖尿病患者应用他汀类药物预防心血管疾病附视频

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute[J] . Sidney C. Smith,Jerilyn Allen,Steven N. Blair,Robert O. Bonow,Lawrence M. Brass,Gregg C. Fonarow,Scott M. Grundy,Loren Hiratzka,Daniel Jones,Harlan M. Krumholz,Lori Mosca,Richard C. Pasternak,Thomas Pearson,Marc A. Pfeffer,Kathryn A. Taubert.Circulation . 2006 (19)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J] . The Lancet . 2005 (9493)

Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin in Subclinical Atherosclerosis—The Rationale and Methodology of the METEOR Study[J] . John Robert Crouse III,Diederick E. Grobbee,Daniel H. O’Leary,Michiel L. Bots,Gregory W. Evans,Mike K. Palmer,Ward A. Riley,Joel S. Raichlen.Cardiovascular Drugs and Therapy . 2004 (3)

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia （ASAP）: a prospective, randomised, double-blind trial[J] . TJ Smilde,S van Wissen,H Awollersheim,MD Trip,JJP Kastelein,AFH Stalenhoef.The Lancet . 2001 (9256)

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute[J] . Sidney C. Smith,Jerilyn Allen,Steven N. Blair,Robert O. Bonow,Lawrence M. Brass,Gregg C. Fonarow,Scott M. Grundy,Loren Hiratzka,Daniel Jones,Harlan M. Krumholz,Lori Mosca,Richard C. Pasternak,Thomas Pearson,Marc A. Pfeffer,Kathryn A. Taubert.Circulation . 2006 (19)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins[J] . The Lancet . 2005 (9493)

Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin in Subclinical Atherosclerosis—The Rationale and Methodology of the METEOR Study[J] . John Robert Crouse III,Diederick E. Grobbee,Daniel H. O’Leary,Michiel L. Bots,Gregory W. Evans,Mike K. Palmer,Ward A. Riley,Joel S. Raichlen.Cardiovascular Drugs and Therapy . 2004 (3)

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia （ASAP）: a prospective, randomised, double-blind trial[J] . TJ Smilde,S van Wissen,H Awollersheim,MD Trip,JJP Kastelein,AFH Stalenhoef.The Lancet . 2001 (9256)